A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
Status:Ongoing
Phase:Open Label
Principal Investigator(s):David Magnuson, PharmD
Objective:This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluation of seroconverters, and collect information regarding whether the seroconverter experienced signs and symptoms of acute HIV-1 infection prior to or at the time of seroconversion.
Start Date
End Date
September 4, 2013
June 4, 2018
Enrollment:150
Age range:
18 Years ↔
any
Population:Cisgender Men, Cisgender Women